Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

A Head-to-Head Comparison of Intralesional Furosemide-Digoxin Versus Polidocanol for the Treatment of Cutaneous Warts With 6-Month Follow-up

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07307131

Enrollment

Registered

2025-12-29

Start date

2024-09-01

Completion date

2025-09-30

Last updated

2026-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Warts, Human Papilloma Virus (HPV)

Keywords

Cutaneous warts, human papillomavirus, intralesional therapy, furosemide, digoxin, polidocanol, sclerotherapy

Brief summary

This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.

Detailed description

This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.

Interventions

DRUGIntralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

DRUGIntralesional polidocanol 2%

Group B (Active Comparator): Intralesional polidocanol 2%

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Masking description

Single (Participant)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients over 18 years of age with single or multiple cutaneous warts.

Exclusion criteria

* History of allergies to the study medications, known cardiac or renal disease, hypertension, pregnancy or lactation, and any signs of systemic or local infection.

Design outcomes

Primary

Measure	Time frame	Description
Complete Clinical Response	Up to 8 weeks	100% clearance of the treated wart at the end of the treatment period.

Secondary

Measure	Time frame	Description
Incidence and Severity of Adverse Effects	Throughout the treatment period (up to 8 weeks)	Assessment of side effects such as pain, erythema, edema, and ulceration.
Recurrence Rate	6 months post-treatment	Rate of wart recurrence at the 6-month follow-up visit

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026